Combining Savella (Milnacipran) with Sertraline: Exercise Extreme Caution
You can prescribe Savella (milnacipran) with sertraline, but this combination requires extreme caution due to the significant risk of serotonin syndrome, which can be life-threatening. Both medications are serotonergic agents—sertraline is an SSRI and milnacipran is an SNRI—and combining them substantially increases serotonin levels in the brain 1, 2.
Understanding the Risk
Serotonin Syndrome: A Potentially Fatal Complication
When combining two serotonergic medications like sertraline and milnacipran, serotonin syndrome can develop within 24-48 hours and presents with a characteristic triad 1:
- Mental status changes: confusion, agitation, anxiety
- Neuromuscular hyperactivity: tremors, clonus, hyperreflexia, muscle rigidity
- Autonomic hyperactivity: hypertension, tachycardia, arrhythmias, tachypnea, diaphoresis, shivering, vomiting, diarrhea
Advanced symptoms include fever, seizures, arrhythmias, and unconsciousness, which can lead to death 1. Treatment requires hospitalization with discontinuation of all serotonergic agents and continuous cardiac monitoring 1.
Clinical Approach to Combination Therapy
If You Decide to Combine These Medications:
Start the second serotonergic drug at a low dose, increase slowly, and monitor intensively for symptoms, especially in the first 24-48 hours after any dosage changes 1. This is the guideline-recommended approach when combining non-MAOI serotonergic drugs 1.
Specific Monitoring Protocol:
- Begin with the lowest available dose of the second medication
- Increase in small increments only after confirming tolerability
- Watch closely during the first 48 hours after initiating or adjusting doses
- Educate the patient about serotonin syndrome symptoms and instruct them to seek immediate medical attention if they develop
Drug Interaction Considerations:
Sertraline has moderate effects on CYP2D6 metabolism 1, while milnacipran has minimal interaction with cytochrome P450 enzymes 3, 4. This means pharmacokinetic interactions are less concerning than the pharmacodynamic risk of serotonin syndrome. Milnacipran is primarily excreted unchanged (approximately 50%) with about 30% as glucuronide and only 20% as oxidative metabolites 3, 4.
Additional Safety Concerns
Bleeding Risk
Both medications increase bleeding risk, particularly when combined with NSAIDs, aspirin, or warfarin 1, 2. Rare bleeding events include ecchymosis, hematoma, epistaxis, petechiae, and hemorrhage 1.
Cardiovascular Effects
Milnacipran can cause increased heart rate, palpitations, and hypertension 2. Monitor blood pressure and heart rate, especially in patients with pre-existing cardiovascular conditions.
Urinary Retention
Men taking milnacipran may experience decreased urine flow or inability to urinate, along with testicular pain or ejaculatory problems 2.
Common Pitfalls to Avoid
- Don't assume the combination is safe just because both drugs are commonly prescribed—the serotonin syndrome risk is real and potentially fatal
- Don't start both medications at full therapeutic doses simultaneously—this dramatically increases risk
- Don't fail to educate patients about warning signs—early recognition can be life-saving
- Don't overlook other serotonergic medications the patient may be taking, including tramadol, fentanyl, dextromethorphan, or even St. John's Wort 1, 2
Clinical Context
While research shows milnacipran and sertraline have been studied together in animal models for analgesic effects 5, and one case report describes switching from sertraline to milnacipran successfully 6, there is no high-quality evidence supporting the safety or efficacy of combining these two medications in humans. The available guidelines consistently emphasize caution when combining any two serotonergic agents 1.
The FDA drug label for Savella explicitly warns about combining it with SSRIs like sertraline and lists this as a significant drug interaction requiring careful monitoring 2.